

## PMC SCIENCE AND PUBLIC POLICY COMMITTEES MEETING AGENDA

Tuesday, December 15, 12:00 – 2:00 p.m. ET

Link to webinar:

<https://permedcoalition.webex.com/permedcoalition/onstage/g.php?MTID=ec7c0a9161ab9757548ac1cb2add6b74b>

(passcode: pmc123)

Dial 202-800-9984 and enter meeting ID 825756

**12:00 p.m. ET Welcome & Introduction**

**Edward Abrahams**

President

Personalized Medicine Coalition

**12:15 p.m. ET Congressional Efforts to Expand Coverage for Personalized Medicine**

- [H.R.4144](#): Ending the Diagnostic Odyssey Act
- [H.R. 4393](#): Advancing Access to Precision Medicine Act

**Adeola Adesina**

Health Policy Advisor

Representative Eric Swalwell (CA-15)

**Michael Reed**

Chief of Staff

Representative Eric Swalwell (CA-15)

**Daniel Zawitoski**

Chief of Staff

Representative Scott Peters (CA-52)

(continued)

1:00 p.m. ET **Business Meeting**

**Cynthia A. Bens**

Senior Vice President, Public Policy

Personalized Medicine Coalition

- **Public Policy Updates**
  - **Congressional Activities**
    - Congressional Personalized Medicine Caucus
    - [Proposal](#) for *Personalizing Medications Act*
  - **Regulation**
    - User fee program reauthorization
      - PMC [comment letter](#) on *Medical Device User Fee Amendments for Fiscal Years 2023 Through 2027* (November 27, 2020)
      - PMC's [remarks](#) during FDA's *Public Workshop on the Seventh Reauthorization of the Prescription Drug User Fee Act* (delivered July 23, 2020)
  - **Coverage and Reimbursement**
    - CMS' *Interim Final Rule for Most Favored Nations Model* (see [Federal Register notice](#))
    - CMS' *Proposed Decision Memo for Blood-Based Biomarker Screening Tests for Colorectal Cancer*
      - PMC [comment letter](#) (November 13, 2020)
    - PalmettoGBA's *Proposed Local Coverage Determination (MoldX) for Minimal Residual Disease Testing for Cancer*
      - PMC [comment letter](#) (November 6, 2020)
    - CMS' *Proposed Medicare coverage of Innovative Technology (MCIT) Pathway for Breakthrough Devices*
      - PMC [comment letter](#) (November 2, 2020)
    - CMS' *Proposed Outpatient Prospective Payment System Rule/Laboratory Date of Service Policy*
      - PMC [comment letter](#) (October 5, 2020)
  - PMC's [Policy Agenda](#) for 2021
  - **Working Group Updates**
    - Pharmaceutical & Diagnostics Working Group
    - Patient Advocacy Organization Working Group

(continued)

**Daryl Pritchard, Ph.D.**

Senior Vice President, Science Policy  
Personalized Medicine Coalition

- **Science Policy Updates**

- [\*The Personalized Medicine Report: Opportunity, Challenges, and the Future \(6<sup>th</sup> Edition\)\*](#)
- [\*Understanding and Delivering the Clinical and Economic Benefits of Personalized Medicine: A Research Program\*](#)
- **Pharmacogenomics**
  - *Pharmacogenomics in Clinical Guidelines and at FDA*
  - *STRIFE: A Collaborative Community in Pharmacogenomics*
- **Reductions in Cancer Screening During the COVID-19 Pandemic**
- **Working Group Updates**
  - Pharmacogenomics Working Group
  - Health Care Working Group

**1:50 p.m. ET    New Business**

- 2021 speaker suggestions

**2:00 p.m. ET    Conclusion**